BioCentury | Apr 26, 2018
Company News

Shire reports first sales after neuroscience, rare disease split

...its neuroscience division fell 2% to $918 million. Excluding sales of ulcerative colitis drug Lialda mesalamine...
BioCentury | Mar 31, 2018
Strategy

Refashioning Takeda

...two reported GI drugs accounting for 54% of those sales. Shire’s largest GI drug, Lialda mesalamine...
BioCentury | Jan 5, 2018
Company News

Allergan cutting jobs ahead of Restasis competition

...cyclosporine ophthalmic emulsion. Other Allergan products facing loss-of-exclusivity headwinds in 2018 include gastrointestinal drug Delzicol mesalamine...
...disease drug Namenda XR memantine. Allergan plc (NYSE:AGN), Dublin, Ireland Business: Ophthalmic Jaime De Leon Aczone Atrisone cyclosporine Dapsone topical gel Delzicol memantine mesalamine Namenda...
BioCentury | Jan 4, 2018
Company News

Allergan cutting jobs ahead of Restasis competition

...cyclosporine ophthalmic emulsion. Other Allergan products facing loss-of-exclusivity headwinds in 2018 include gastrointestinal drug Delzicol mesalamine...
BioCentury | Jun 16, 2017
Company News

GeneriCo wins IPR for Apriso

...PTAB) invalidated all claims in U.S. Patent 8,865,688 covering ulcerative colitis (UC) drug Apriso granulated mesalamine...
...Freiburg, Germany) (see BioCentury, March 23, 2009 & April 6, 2015 ). Apriso, which is mesalamine...
BioCentury | Oct 10, 2016
Company News

Cosmo, Shire autoimmune news

...PTO) upheld the validity of the only Orange Book-listed patent for ulcerative colitis drug Lialda mesalamine...
...and is owned by Cosmo’s Cosmo Technologies Ltd. subsidiary. Shire markets Lialda, which is 5-ASA mesalamine...
BioCentury | Oct 6, 2016
Company News

PTAB upholds Lialda patent's validity

...Office upheld the validity of the only Orange Book-listed patent for ulcerative colitis drug Lialda mesalamine...
...Cosmo Technologies Ltd. subsidiary of Cosmo Pharmaceuticals N.V (SIX:COPN). Shire markets Lialda, which is 5-ASA mesalamine...
BioCentury | Apr 25, 2016
Politics, Policy & Law

SCOTUS to the rescue?

...from Pernix [1] (A) Kerydin tavaborole from Anacor [3] Enbrel etanercept from Amgen [1] Lialda mesalamine...
BioCentury | Apr 4, 2016
Company News

Allergan, Shire autoimmune news

...for the District of Southern Florida upheld a patent protecting Shire’s ulcerative colitis drug Lialda mesalamine...
...year. Shire recorded $684.4 million in worldwide sales of Lialda in 2015. The 5-aminosalicylate (5-ASA) mesalamine...
BioCentury | Mar 30, 2016
Company News

District court again sides with Shire in Lialda dispute

...The U.S. District Court of Southern Florida upheld a patent protecting ulcerative colitis drug Lialda mesalamine...
...case this year (see BioCentury Extra, Oct. 16, 2015) . Lialda is a 5-aminosalicylate (5-ASA) mesalamine...
Items per page:
1 - 10 of 167